Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Neumología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
Fase 3
ClinicalTrials.gov
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)
INTERVENTIONAL
Inicio: 11 de ago de 2025
ID: NCT07099898
Completado
Fase 3
ClinicalTrials.gov
A Phase IIIB, 12-Month, Double-blind, Double-dummy,Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 μg x 2 Actuations Twice-daily and 80/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler® 4.5 μg x 2 Inhalations Twice-daily in COPD Subjects
INTERVENTIONAL
Inicio: 1 de ene de 2007
ID: NCT00419744
Completado
ClinicalTrials.gov
An International Observational Study of Outpatients With SARS-CoV-2 Infection
OBSERVATIONAL
Inicio: 18 de jun de 2020
ID: NCT04385251
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Randomized Double-blind, 2-part, Multicenter Study to Compare the Efficacy of ZD6474 With the Efficacy of ZD1839 (Iressa™) in Subjects With Locally Advanced or Metastatic (IIIB/IV) Non-small Cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy and to Assess the Activity of ZD6474 in Subjects Following Failure of Treatment With ZD1839.
INTERVENTIONAL
Inicio: 1 de may de 2003
ID: NCT00059722
Completado
Fase 2
ClinicalTrials.gov
A Randomized Study of Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation Therapy in Stage III Unresectable NSCLC
INTERVENTIONAL
Inicio: 1 de mar de 2003
ID: NCT00191139
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
INTERVENTIONAL
Inicio: 24 de may de 2024
ID: NCT06376045
Completado
Fase 2
ClinicalTrials.gov
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
INTERVENTIONAL
Inicio: 5 de oct de 2021
ID: NCT05037929
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease
INTERVENTIONAL
Inicio: 1 de ene de 2012
ID: NCT01456325
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
INTERVENTIONAL
Inicio: 30 de sept de 2020
ID: NCT04487080
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 24 de oct de 2025
ID: NCT06793215
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-Blind Active-Controlled (Enoxaparin), Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery
INTERVENTIONAL
Inicio: 1 de nov de 2006
ID: NCT00371683
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once-Daily Orally Administered PH-797804 (0.5, 3, 6 And 10 MG) In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).
INTERVENTIONAL
Inicio: 1 de feb de 2008
ID: NCT00559910
Reclutando
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis
INTERVENTIONAL
Inicio: 17 de sept de 2024
ID: NCT06632444
Completado
Fase 3
ClinicalTrials.gov
Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC
INTERVENTIONAL
Inicio: 4 de mar de 2017
ID: NCT02998528
Completado
Fase 3
ClinicalTrials.gov
DB2114930: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
INTERVENTIONAL
Inicio: 1 de mar de 2013
ID: NCT01817764
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)
INTERVENTIONAL
Inicio: 14 de dic de 2017
ID: NCT03302234
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
INTERVENTIONAL
Inicio: 6 de dic de 2018
ID: NCT03800134
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).
INTERVENTIONAL
Inicio: 24 de oct de 2023
ID: NCT05984277
Completado
ClinicalTrials.gov
A Prospective Epidemiological Study of Pregnancy Outcomes and of Events of Interest in Pregnant Women, Neonates and Infants (PEPNI)
INTERVENTIONAL
Inicio: 30 de may de 2019
ID: NCT03614676
Reclutando
Fase 3
ClinicalTrials.gov
PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
INTERVENTIONAL
Inicio: 29 de sept de 2025
ID: NCT07144280
Anterior
1
...
12
13
14
...
434
Siguiente
Filtros